Artificial intelligence and allied subsets in early detection and preclusion of gynecological cancers

P Garg, A Mohanty, S Ramisetty, P Kulkarni… - … et Biophysica Acta (BBA …, 2023 - Elsevier
Gynecological cancers including breast, cervical, ovarian, uterine, and vaginal, pose the
greatest threat to world health, with early identification being crucial to patient outcomes and …

Implications of Toll-like receptors (TLRs) and their signaling mechanisms in human cancers

SA Chandrasekar, T Palaniyandi… - … -Research and Practice, 2023 - Elsevier
Most essential pattern-recognition receptors regulating innate immune functions are toll-like
receptors (TLRs). TLRs are characterized by lack of concurrent epithelial markers and are …

A systematic review of family history, race/ethnicity, and genetic risk on prostate cancer detection and outcomes: considerations in PSA-based screening

NJ Graham, LH Souter, SS Salami - Urologic Oncology: Seminars and …, 2024 - Elsevier
Aim To investigate the role of family history, race/ethnicity, and genetics in prostate cancer
(PCa) screening. Methods We conducted a systematic review of articles from January 2013 …

LncRNAs in modulating cancer cell resistance to paclitaxel (PTX) therapy

AG Alkhathami, H Pallathadka, S Shah, S Ganesan… - Medical Oncology, 2025 - Springer
Paclitaxel (PTX) is widely used for treating several cancers, including breast, ovarian, lung,
esophageal, gastric, pancreatic, and neck cancers. Despite its clinical utility, cancer …

The risk factors and screening uptake for prostate Cancer: a sco** review

S Mumuni, C O'Donnell, O Doody - Healthcare, 2023 - mdpi.com
Objectives: The purpose of this sco** review was to identify the risk factors and screening
uptake for prostate cancer. Design: Sco** review. Methods: Arksey and O'Malley's …

Oncogenic role of FOXM1 in human prostate cancer

DY Lee, JN Chun, I So, JH Jeon - Oncology Reports, 2023 - spandidos-publications.com
Prostate cancer is the leading cause of cancer-related mortality among men worldwide. In
particular, castration-resistant prostate cancer presents a formidable clinical challenge and …

[HTML][HTML] Heme Oxygenase-1 and Prostate Cancer: Function, Regulation, and Implication in Cancer Therapy

RJ Salloom, IM Ahmad, DZ Sahtout, MJ Baine… - International Journal of …, 2024 - mdpi.com
Prostate cancer (PC) is a significant cause of mortality in men worldwide, hence the need for
a comprehensive understanding of the molecular mechanisms underlying its progression …

JUN mediates the senescence associated secretory phenotype and immune cell recruitment to prevent prostate cancer progression

T Redmer, M Raigel, C Sternberg, R Ziegler, C Probst… - Molecular Cancer, 2024 - Springer
Background Prostate cancer develops through malignant transformation of the prostate
epithelium in a stepwise, mutation-driven process. Although activator protein-1 transcription …

Identification of mitochondrial carrier homolog 2 as an important therapeutic target of castration-resistant prostate cancer

Y Liu, A Chen, Y Wu, J Ni, R Wang, Y Mao, N Sun… - Cell Death & …, 2025 - nature.com
We here investigate the expression of the mitochondrial carrier homolog 2 (MTCH2) and its
potential function in castration-resistant prostate cancer (CRPC). Bioinformatic analyses …

Enhancing Urological Cancer Treatment: Leveraging Vasodilator Synergistic Potential with 5-FU for Improved Therapeutic Outcomes

E Ribeiro, B Costa, L Marques… - Journal of Clinical …, 2024 - pmc.ncbi.nlm.nih.gov
Backgroud: This study investigates the potential of vasodilator drugs as additive therapy in
the treatment of urological cancers, particularly in combination with the antineoplastic agent …